Cloning and expression of human vasohibin1 gene in E. coli by Malmir 1, Somaye et al.
 I J H S 








International Journal of Health Studies 
Cloning and Expression of Human Vasohibin1 Gene in E. coli 
Somaye Malmir1, Ali Zarei Mahmodabadi1, Masoomeh Masoomikarimi2, Soheilaalsadat Mirhoseini Ardakani3, Elmira Roshaniasl4, Shahnaz 
Shekarforoush3, Moslem Jafarisani5*, Reza Ahmadi6 
1 Biotechnology Research Center, Baqiyatallah University of Medical Science, Tehran , Iran. 
2 Dept. of Basic science, Torbat Heydariyeh University of Medical science, Torbat heydariyeh, Iran 
3 Dept. of Biology, School of Basic Sciences, Karaj Branch, Islamic Azad University, Alborz, Iran. 
4 Dept. of Biochemistry, School of Medicine, Uremia University of Medical Sciences, Uremia, Iran. 
5 School of Medicine, Shahroud University of Medical Science, Shahroud, Iran. 
6 School of Medicine, Iran University of Medical Science, Tehran, Iran. 
Received: 10 May 2016 
Accepted: 14 June 2016 
 
Abstract 
Background: Angiogenesis is an important process in various 
physiologic and pathologic states. The most significant stimulator of 
angiogenesis is vascular endothelial growth factor (VEGF). In 
contrast, vasohibin1 acts as an angiogenesis inhibitor which 
specifically inhibits new vessels formation. The aim of the present study 
was cloning and expression of vasohibin1 gene in E. coli as well as 
purification of recombinant vasohibin1 protein. 
Methods: Total RNA was extracted from human umbilical vein 
endothelial cells and cDNA was synthesized by RT-PCR. cDNA was 
amplified using a specific designed primer set. The PCR product was 
evaluated by electrophoresis and then cloned in pET28a expression 
vector which transformed into E.coli BL21 (DE3) as a host. IPTG is 
used as an expression inducer in media. Alternatively, PCR products 
were analyzed by sequencing and double digestion with EcoRI and 
HindIII restriction endonuclease. The expressed protein was purified 
by Ni-NTA column and confirmed by SDS Page and western blotting. 
Evaluation of gene inhibition was carried out through western blottting 
and RT-PCR. 
Results: No mutation or sequence variants were found in PCR 
products as a result of sequencing analysis. Moreover, the quantity and 
quality of expressed recombinant protein in the presence of IPTG with 
selected vector in E. coli was high. VASH1 significantly prevented the 
receptor expression. The quality and level of expressed protein in 
pET28 expression vector indicated the efficacy of the applied system in 
vasohibin1 production. 
Conclusions: The produced vasohibin1 protein probably can be used 
as an angiogenesis inhibitor in further studies on retinopathies. 
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Introduction 
Angiogenesis is the formation of new blood vessels from 
pre-existing ones. It plays a central role in the progression of 
various chronic inflammatory diseases, including diabetic 
retinopathy.1 So, inhibition of angiogenesis may provide a 
rational approach to manage these diseases. 
Induction of vascular endothelial growth factor (VEGF) by 
hypoxia triggers both physiological and pathological 
angiogenesis.2 VEGF plays a major role in the development of 
choroidal neovascularization.3 Therefore, VEGF inhibition has 
received the most attention in relation to potential anti-
angiogenesis/anti-tumor therapy. Negative feedback regulation 
is one of the most important physiological mechanisms with 
which bodies are endowed, and has been demonstrated to 
control a wide range of phenomena.4 
VEGF family members function through the activation of 
VEGF receptor-1 (VEGFR-1) and VEGF receptor-2 (VEGFR-
2), which are particularly expressed on vascular endothelial 
cells (ECs), and VEGF receptor-3 (VEGFR-3), which is 
restricted to lymphatic endothelium.5 In stimulating EC 
proliferation and migration, VEGFR-2 is more effective than 
VEGFR-1,6 and is markedly expressed during tumor growth, 
chronic inflammation, and wound repair.7 
Vasohibin1 (VASH1) is induced by VEGF mediated by 
protein kinase C- δ downstream of VEGFR-2.8 It is a protein 
with 42 KD and 365 amino acids which can produce in 
different types of cells. The mode of VASH secretion is 
unconventional since VASH does not have a classical signal 
sequence.9 It inhibits migration and proliferation of endothelial 
cells in culture and exhibits a potent antiangiogenic activity in 
vivo.10 It might be deposed in the extracellular matrix (ECM) or 
be released into the blood to inhibit angiogenic processes of 
ECs.11 VASH1 can reduce VEGFR-2 mRNA expression and 
then block VEGF-A (Hosaka et al., 2009). Thus, it has been 
assumed that VASH1 functions as a negative feedback 
inhibitor of angiogenesis and might be a promising candidate 
structure for antiangiogenic therapies.11-12 
In our previous study, we reduced expression of VEGFR-1 
and VEGFR-2.14-17 At present, VEGF is an important target to 
control vascular growth in vivo. The aim of this study was to 
clone and express VASH1 protein in order to inhibit the 
expression of VEGFR-2 in vitro for investigation of its anti-
neovascularization effects in future studies. 
Materials and Methods 
The materials used and their sources were as follows: LB 
medium, LB agar, E. coli (DE3), kanamycin antibiotic, and 
VEGF165 were purchased from Sigma Co. pET28a(+) Plasmid 
was obtained from vector bank of the Pasteur Institute, Iran. 
The restriction enzymes including FastDigest EcoRI and 
FastDigest HindIII, Taq polymerase and T4 ligase, were 
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purchased from Fermentas Co. TAE, TE buffer, CTAB/NaCl 
buffer, agarose Gel SDS and phenol were purchased from 
Sigma, Roche and Fermentase Co. RNAs were isolated using 
RNeasy Mini kit (QIAGEN, Hilden, Germany). RT-PCR was 
performed using RNA PCR kit (AMV) (version 3.0; TaKaRa 
Bio, Otsu, Japan). 
The following primers were designed with OLIGO primer 
analysis software based on the VASH1 gene sequence 
published in NCBI. 
Forward primer: 5ʹ AGA-TGA-ATT-CAT-GCC-AGG-
GGG-GAA-GAA 3ʹ; Reverse primer: 5ʹ GGC-AAA-GCT-
TTC- AGA-CCC-GGA-TCT-GGT 3ʹ 
Additionally, all restriction enzyme cutting sites among the 
gene sequence were analyzed by DNAsis software. The 
specificity of designed primers was checked by aligning their 
sequence with the subjected sequence available in BLAST. 
HUVECs as a source of VASHI were cultured in PRMI 
1640 medium and then stimulated with hypoxia and VEGF to 
induce the expression of VASH1 mRNA. Total RNA was 
extracted by RNA extraction kit. The cDNA was then 
synthesized by RT-PCR and amplified using PCR and specific 
primers. In this stage, Tag sequences containing recognition 
sites for restriction of endonuclease EcoR I and HindIII were 
introduced into both ends of the gene. PCR product was 
evaluated by electrophoresis on 1% agarose gel. 
Pure PCR products and pET28a vector were digested with 
EcoRI and HindIII restriction endonucleases, and then ligated 
with T4 DNA ligase followed by transforming into E. coli 
BL21 (DE3) using electroporation (Biorad, USA). After adding 
1 ml SOC medium, they were placed in a 2 ml microtube and 
incubated at 37 °C for 2 h. 
Transformed cells were centrifuged at max speed. Cell 
pellets were cultured in LB-Agar medium containing 40 µg/ml 
kanamycin at 37 °C for 24 h. Colonies able to grow in the 
presence of kanamycin were selected. In order to confirm 
cloning, PCR was performed on the vector as template using 
specific primers. A PCR product with 1098 bp in length 
indicates gene cloning in the vector. 
With regard to the aim of the study; the expression of 
protein for use in future studies, evaluation of possible 
mutation was necessary. Following cloning and amplification 
of the cloned vector and prior to transforming into the host, the 
gene was sequenced by Macrogen (Korea) Company. 
Colonies of 50 µl with positive PCR were added to 5 ml 
LB-broth containing 25 µl kanamycin and incubated at 37 °C 
for 2 h on a rotary shaker (150 rpm) to reach OD 0.6 at 600 nm. 
After adding 50 µl isopropyl-β-D-thiogalactoside (IPTG), the 
cells were incubated at 37 °C for 15 h on a rotary shaker (150 
rpm). The cells were harvested and lysed in PBS PH 7.6 by 
high-pressure homogenizer. Afterward, cells were centrifuged 
at 4 °C (20 min, 12,000 g). The isolated inclusion bodies were 
washed twice with Tris solution (1.21 g per 100 ml distilled 
water) containing 0.186 g EDTA, 0.077g DTT at PH7 for the 
first time, and then containing 0.186 g EDTA, 0.077g DTT and 
6 M urea the second time. Finally, the inclusion bodies were 
dissolved in 5 ml extraction buffer containing 8 M urea and 
dialyzed overnight at 4 °C to remove urea and produce proper 
folding in the protein. 
His-tagged recombinant protein was added to NI column 
(16 * 125 mm), and then removed by adding 250 mM imidazol. 
The success of the purification was confirmed by SDS-PAGE 
electrophoresis and western blot analysis using antihistidine 
antibody.  
To determine the effects of VASH1 on VEGFR-2, 
HUVECs were serum-starved overnight and incubated with 
purified recombinant VASH1 for 90 min, followed by 50 
ng/mL VEGF165 treatment for 10 min. Cells were lysed with 
buffer containing 1% Triton X-100, 1% deoxycholate and 
proteinase inhibitor cocktail (Sigma). After centrifuge at 5,000 
g, supernatant was used for western blotting, according to the 
Saito et al.18 
HUVECs grown to 50% confluence were incubated either 
without or with VASH1 at appropriate concentrations for 3 
days. The cells were then lysed and their total RNAs were 
isolated using RNeasy mini kit (QIAGEN, Hilden, Germany), 
according to the manufacturer’s instructions. RT-PCR was 
performed using RNA PCR kit (AMV) (version 3.0; TaKaRa 
Bio, Otsu, Japan). Briefly, total RNAs were converted to 
cDNA at 50 °C for 30 min with reverse transcriptase and oligo-
dT primer. Reverse transcription mixtures were subjected to 
PCR with specific primers. Reactions were incubated at 94 °C 
for 2 min and then were amplified using temperature 
parameters of 94 °C for 30 s, 60 °C for 30 s, and 72 °C for 30 s. 
Amplifications were carried out for 35 cycles, followed by a 7-
min extension at 72 °C. The products were separated by 1.5% 
agarose gel electrophoresis staining with 1 μg/ml ethidium 
bromide and visualized with a UV transilluminator.18 
Results  
After design and synthesis of specific primers for VASHI, 
the first total RNA was extracted from HUVECs. Then cDNA 
was synthesized by RT-PCR. By using specific primers, PCR 
product size of 1,098 bp was obtained (Figure.1). 
 
Figure 1. PCR product of vasohibin1- specific primers with 1098 bp length (Lane 
1), Negative control without any cDNA (Lane 2) and High range DNA Ladder (Lane 3) 
pET28a vector was used for gene cloning. The vector was 
amplified and purified in E. coli. On the basis of the genetic map 
of the vector, correct plasmid construction was verified by PCR 
and Rsai restriction enzyme. Restriction digestion with this 
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enzyme produced three fragments: 1,270 bp; 3,030 bp; 4,261 bp. 
The vector was also digested by EcorI and HindIII (Figure 2). 
 
Figure 2. Restriction digestion of pET28a (Lane 1: High range DNA ladder; Lane 
2: pET28a vector without enzymatic digestion; Lane 3: The produced banding 
patterns by restriction endonuclease digestion with Rsai (1270, 3030 and 4261 
bp); Lane 4: Double digestion of pET28a vector by E.CorI and HindIII) 
After vector confirmation using the restriction enzyme EcorI 
and HindIII, PCR product and vector were digested and ligated 
together with ligase followed by transforming into E. coli 
Growing colonies in LB-Agar medium containing kanamycin 
were purified and the cloned gene was analyzed by PCR. The 
1,098 bp band indicates cloning accuracy (Figure.3) 
 
Figure 3. The electrophoretic pattern of PCR products of grown colonies in LB-
Agar medium with 40 µgr/µl kanamycin (The 1098 bp band indicates cloning 
accuracy) 
The cloned vector was also digested and the bands related to 
gene and vector body confirmed them (Figure. 4). To evaluate 
mutation in the cloned gene, the fragments were sequenced and 
the results did not represent any non-sense mutation among the 
sequence (Figure.5). 
Figure 4. The electrophoretic pattern of enzymatic digestion of recombinant 
plasmid on 1% agarose gel (Lane 1: purified plasmid; Lane 2: digested plasmid. 
Band with 1098 bp showed) 
 
Figure 5. Nucleotide sequence of the cloned gene in pET28a vector. (Line 1: 
Native gene Sequence from NCBI gene bank; Line 2: Cloned Gene Sequences; 
Line 3: PCR product sequences) 
After confirming cloning, vector was transformed into the 
host and the cells were cultured with or without IPTG. The cells 
were harvested and lysed to make the cellular extract. After 
Malmir et a 
International Journal of Health Studies 2016;2(3)      |      34 
electrophoresis, the results were shown the expression of protein 
with IPTG in transfected cells (Figure. 6). Recombinant protein 
was purified by NI chromatography column (Figure. 7) and was 
analyzed by using antihistidine antibody and western blotting 
(Figure 8). 
 
Figure 6. The analysis of VASH1 protein expression in E.coli (Lines 1,4: Induced 
cells with IPTG; Lines 2,5: un-induced cells; Line 3: protein marker; SM0671) 
 
Figure 7.  Recombinant protein purification by using Ni-NTA column (Lane 1: 
An output of buffer D; Lane 2: An output of buffer E; Lane 3: protein marker; 
SM0671; Lane 4: A protein sample before transforming from chromatography 
column) 
 
Figure 8. The result of western blotting of expressed VASH1 protein (Lane 1: 
Induced cells with IPTG; Lane 2: Uninduced cells; Lane 3: Protein marker, 
SM0671) 
Discussion 
We have successfully cloned and expressed VASH1 as a 
recombinant in the prokaryotic host cell. The expression of 
proteins in E. coli is most widely and routinely used.19 VASH1 
has been identified as a target gene of VEGF in human 
umbilical vein endothelial cells.9 The VASH negative feedback 
loop that modulates VEGF activity involves reduction of 
mRNA for VEGF-2. This can be achieved by inhibiting 
expression or by enhancing degradation of VEGF-2 RNA.20 
The administration of exogenous VASH1 strongly inhibits 
pathological and physiological angiogenesis without any 
significant side effects.21 Furthermore, bolstering endogenous 
levels of VASH by injecting recombinant VASH1 or by 
administration of an adenoviral vector containing a vasohibin 
expression cassette, significantly suppressed retinal 
neovascularization.20 VASH1 protein does not contain any 
classical signal sequence, as same as other secreted proteins.22 
Also, it does not colocalize with the endoplasmic reticulum11 
marker calnexin, suggesting that VASH1 might be transported 
and released into the extracellular space via an unconventional 
secretary pathway.9 
pET expression system is one of the common systems of 
cloning and expression of recombinant proteins in E. coli with 
specific properties including T7Lac promoter and 6 His Taq 
marker. The E.coli strains H5a (DE3) plysS, DH5a (DE3), 
BL21 (DE3) plysS, and BL21 (DE3) with lambda phage are 
able to express viral RNA polymerase.23 In the present study, 
the VASH1 gene was cloned into pET28a expression vector 
and transformed into E. coli BL21 (DE3), where it was induced 
to express VASH1 protein by IPTG. With careful choice of 
host strains, vectors, and growth conditions, most recombinant 
proteins can be cloned and expressed at high levels in E .coli. 
However, many polypeptide gene products expressed in E. coli 
accumulate as insoluble aggregates that lack functional 
activity.24 So, a primary consideration for recombinant protein 
expression and purification is the experimental purpose for 
which the protein will be utilized. For biochemical and 
structural studies, it is often important to optimize conditions 
for the expression of soluble, functionally active protein, 
whereas for antigen production, the protein can be expressed 
either in native or denatured form.25 The expressed protein 
migrated on SDS-PAGE at a position consistent with its 
molecular weight 45 KD. The number of bases which added to 
the cloned gene through ATG initiation codon, was 102 bases 
(34 amino acids) to add 3740 Da to the VASH1 molecular 
weight. This increase was the least of additional polypeptides 
in comparison to other studies. It can be cleaved by thrombin 
protein to enhance protein properties. 
Human VASH1 gene was properly cloned in pET28a 
expression vector. The VASH1 recombinant protein was 
expressed in E. coli with proper concentration of IPTG. So, this 
recombinant system is a desired system for expressing this 
protein as soluble form. This work will definitely help those 
researchers who are all working with VASH1 worldwide and 
also with our future studies on VASH1 
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